Aptiganel

Aptiganel
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-yl-guanidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H21N3
Molar mass303.409 g·mol−1
3D model (JSmol)
  • CCC1=CC(=CC=C1)N(C)C(=NC2=CC=CC3=CC=CC=C32)N
  • InChI=1S/C20H21N3/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19/h4-14H,3H2,1-2H3,(H2,21,22) checkY
  • Key:BFNCJMURTMZBTE-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke due to its neuroprotective effects. However, despite positive results in animal studies, human trials showed limited efficacy and undesirable side effects such as sedation and hallucinations, leading to the discontinuation of clinical development.

Chemistry

Synthesis

Aptiganel synthesis:

1-Naphthylamine is reacted with cyanogen bromide to give 2. Treatment of this intermediate with 3-ethyl-N-methylaniline leads to addition to the cyano group and formation of the corresponding diaryl guanidine, aptiganel, 3.

History

The drug's failure led to the collapse of Cambridge Neuroscience in 1998 and its eventual sale to CeNeS Pharmaceuticals in 2000.

See also